Bausch & Lomb Corp BLCO
We take great care to ensure that the data presented and summarized in this overview for Bausch & Lomb Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLCO
View all-
Deutsche Bank Ag\ Frankfurt Am Main, 2M3.5MShares$39.5 Million0.02% of portfolio
-
Icahn Carl C Sunny Isles Beach, FL3.5MShares$39.5 Million0.68% of portfolio
-
Alberta Investment Management Corp Edmonton, A03.27MShares$36.9 Million0.36% of portfolio
-
Goldentree Asset Management LP New York, NY2.25MShares$25.4 Million2.88% of portfolio
-
Maple Rock Capital Partners Inc. Toronto, A61.97MShares$22.3 Million1.1% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.88MShares$21.2 Million0.03% of portfolio
-
Whitebox Advisors LLC Minneapolis, MN1.62MShares$18.3 Million1.27% of portfolio
-
River Road Asset Management, LLC1.59MShares$18 Million0.33% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA1.52MShares$17.2 Million0.02% of portfolio
-
Ubs Group Ag1.43MShares$16.2 Million0.0% of portfolio
Latest Institutional Activity in BLCO
Top Purchases
Top Sells
About BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Insider Transactions at BLCO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2025
|
Brent L Saunders CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+2.88%
|
-
|
|
May 22
2025
|
Brent L Saunders CEO and Chairman of the Board |
BUY
Open market or private purchase
|
Direct |
22,000
+2.97%
|
$242,000
$11.28 P/Share
|
|
May 02
2025
|
Andrew C. Von Eschenbach Director |
BUY
Open market or private purchase
|
Direct |
1,695
+3.9%
|
$18,645
$11.76 P/Share
|
|
May 01
2025
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,887
+3.66%
|
$20,757
$11.59 P/Share
|
|
May 01
2025
|
Russel C Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,210
+4.72%
|
$24,310
$11.59 P/Share
|
|
Apr 24
2025
|
A Robert D Bailey EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,781
-5.42%
|
$127,153
$13.89 P/Share
|
|
Apr 24
2025
|
Andrew J. Stewart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,954
-5.91%
|
$51,402
$13.89 P/Share
|
|
Feb 28
2025
|
Luc Bonnefoy President,Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
4,139
-2.66%
|
$66,224
$16.0 P/Share
|
|
Feb 26
2025
|
Luc Bonnefoy President,Surgical |
BUY
Grant, award, or other acquisition
|
Direct |
23,423
+22.98%
|
-
|
|
Feb 26
2025
|
Frederick Munsch SVP, Controller and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
18,581
+20.67%
|
-
|
|
Feb 26
2025
|
Sam Eldessouky EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
59,459
+17.4%
|
-
|
|
Feb 26
2025
|
A Robert D Bailey EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,540
+18.35%
|
-
|
|
Feb 26
2025
|
Yehia Hashad EVP of R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
25,225
+17.42%
|
-
|
|
Feb 26
2025
|
Andrew J. Stewart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,423
+25.94%
|
-
|
|
Feb 26
2025
|
Brent L Saunders CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
168,168
+19.43%
|
-
|
|
Dec 23
2024
|
Andrew J. Stewart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,524
-5.49%
|
$42,908
$17.83 P/Share
|
|
Dec 23
2024
|
Yehia Hashad EVP of R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,075
-2.59%
|
$86,275
$17.83 P/Share
|
|
Dec 23
2024
|
Frederick Munsch SVP, Controller and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,100
-2.81%
|
$52,700
$17.83 P/Share
|
|
Dec 23
2024
|
Brent L Saunders CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
98,431
-8.11%
|
$1,673,327
$17.83 P/Share
|
|
Dec 23
2024
|
A Robert D Bailey EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,402
-3.05%
|
$74,834
$17.83 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 555K shares |
|---|---|
| Open market or private purchase | 55.9K shares |
| Payment of exercise price or tax liability | 160K shares |
|---|